The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$812,546 Vol.
30. September
2%
31. Dezember
22%
$812,546 Vol.
30. September
2%
31. Dezember
22%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Abwickler
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Abwickler
0x65070BE91...The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert



Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen